|
WO2021073498A1
|
|
Egfr inhibitor, composition, and method for preparation thereof
|
|
WO2021057975A1
|
|
Mutant idh2 inhibitor and application thereof
|
|
WO2021057882A1
|
|
Egfr inhibitor, composition and preparation method therefor
|
|
WO2021018003A1
|
|
Egfr inhibitor, composition, and preparation method therefor
|
|
WO2021018009A1
|
|
Egfr inhibitor, composition, and preparation method therefor
|
|
WO2020216190A1
|
|
Quinazoline compound and pharmaceutical application thereof
|
|
WO2020200191A1
|
|
Egfr inhibitors, compositions and methods there of
|
|
WO2020156323A1
|
|
Immunomodulators, compositions and methods thereof
|
|
WO2020156242A1
|
|
Shp2 inhibitor and application thereof
|
|
WO2020156243A1
|
|
Shp2 inhibitor and application thereof
|
|
CN111499634A
|
|
Quinazoline compound and application thereof in medicine
|
|
WO2020156162A1
|
|
Mek inhibitor and pharmaceutical use thereof
|
|
WO2020147702A1
|
|
Egfr inhibitors, compositions and methods thereof
|
|
TW202033526A
|
|
Tyrosine kinase inhibitors, compositions and methods there of
|
|
WO2020063788A1
|
|
Fgfr4 inhibitor and use thereof
|
|
AU2019339703A1
|
|
Immunomodulators, compositions and methods there of
|
|
TW202024084A
|
|
Salt form and crystal form of novel azatricyclic compound and use thereof
|
|
WO2020015716A1
|
|
Immunomodulators, compositions and methods thereof
|
|
WO2020015717A1
|
|
Immunomodulators, compositions and methods thereof
|
|
WO2020011243A1
|
|
Immunomodulators, compositions and methods thereof
|
